VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Optimizing Checkpoint Inhibition in NSCLC

Panelists: Robert Dreicer, MD, Cleveland Clinic; Omid Hamid, MD, Angeles Clinic;Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, UPMC; Louis
Published: Friday, Jan 23, 2015
For High-Definition, Click
The response rate with PD-1 inhibition in non-small cell lung cancer (NSCLC) is approximately 20% to 40%, depending on PD-L1 status. For patients who do not respond to single-agent PD-1 inhibition, combination strategies could be utilized to further improve outcomes.
 
The Lung-MAP study is currently assessing various treatment options based on molecular characteristics. In addition to immunotherapy, this study will also assess platinum-based chemotherapy.
 
View the video, to hear the discussion.


Slider Left
Slider Right
For High-Definition, Click
The response rate with PD-1 inhibition in non-small cell lung cancer (NSCLC) is approximately 20% to 40%, depending on PD-L1 status. For patients who do not respond to single-agent PD-1 inhibition, combination strategies could be utilized to further improve outcomes.
 
The Lung-MAP study is currently assessing various treatment options based on molecular characteristics. In addition to immunotherapy, this study will also assess platinum-based chemotherapy.
 
View the video, to hear the discussion.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x